Efficiency of endovascular stenting in the treatment of malignancy related vena cava superior syndrome: single center experience

Ali Ayberk Besen

doi:10.21601/ortadogutipdergisi.457666

ORTADOĞU TIP DERGİSİ - ORTADOGU MEDICAL JOURNAL

Efficiency of endovascular stenting in the treatment of malignancy related vena cava superior syndrome: single center experience

Malignite ilişkili vena kava superior sendromunun tedavisinde stent uygulanmasının etkinliği: tek merkez deneyimi

Ali Ayberk Besen ¹ ^*

More Detail

Ortadogu Tıp Derg, Volume 10, Issue 4, pp. 449-453

https://doi.org/10.21601/ortadogutipdergisi.457666

OPEN ACCESS

Download Full Text (PDF)

Abstract

Aim: To evaluate efficacy of the endovascular stenting for symptomatic treatment of malignancy-related vena cava superior (VCS) syndrome.
Material and Method: Thirty-five patients who underwent endovascular stenting at Baskent University between December 2005 and October 2016 due to malign VCS were evaluated retrospectively.
Results: A total of 54 stenting procedures were performed in 35 patients. 48% of the patients had a single stent and 43% had two stents. Of the patients on stenting, 6 were women and 29 were men. 68% of all patients were stage 4, and 77% were patients with lung cancer. Symptomatic relief was observed in 31 (89%) patients after the procedure. Re-stenting was performed in four patients for stent thrombosis and in two patients for tumor ingrowth. After stenting, 23 patients were given anti-coagulant treatment. Median overall survival (OS) was 20 weeks (range, 6.5-33.4) in the whole group. In patients with lung cancer, OS after stenting was found to be numerically shorter than other groups, but it did not reach statistical significance.
Conclusion: Endovascular stenting in the palliative treatment of malignancy-related VCS syndrome is an effective treatment method with high clinical success and low morbidity both in newly diagnosed patients and in patients on progression.

Keywords: vena cava superior syndrome, stent, lung cancer

Öz

Amaç: Malignite ilişkili vena kava superior (VKS) sendromunun semptomatik tedavisinde endovasküler stent uygulanan hastalarda bu yaklaşımın etkinliğini değerlendirmeyi amaçladık.
Gereç ve Yöntem: Malign VKS sendromu nedeniyle Başkent Üniversitesinde Aralık 2005- Ekim 2016 tarihleri arasında endovasküler stent uygulanan 35 hasta retrospektif olarak incelenmiştir.
Bulgular: 35 hastaya toplam 54 stent işlemi gerçekleştirilmiştir. Hastaların %48’ine tek stent %43’üne ise iki stent konulmuştur. Stent uygulanan hastaların 6’sı kadın 29’u ise erkekti. Tüm hastaların %68’ini evre 4, %77’sini akciğer kanserli hastalar oluşturmuştur. İşlem sonrası 31 (%89) hastada semptomatik rahatlama gözlenmiştir. Hastaların takibinde 4 hastada stent trombozu 2 hastada ise tümör basısı nedeni ile re-stent ihtiyacı olmuştur. Stent sonrası 23 hastaya anti-koagülan tedavi verilmiştir. Tüm grupta ortanca genel sağkalım (GSK) 20 hafta (aralık 6,5-33,4 ) olarak bulunmuştur. Stent sonrası akciğer kanserli hastalarda GSK diğer gruplara göre sayısal olarak daha kısa olarak bulunmuş ancak istatistiksel anlamlılığa ulaşmamıştır.
Sonuç: Malignite ilişkili VKS sendromunun palyatif tedavisinde endovasküler stent uygulanması tanı anında ya da progresif hastalık durumunda yüksek klinik başarı ve düşük morbidite ile etkin bir tedavi yöntemidir.

Keywords: Vena kava superior sendromu, stent, akciğer kanseri

References

Cheng S. Superior vena cava syndrome: a contemporary review of a historic disease. Cardiol Rev, 2009; 17: 16-23.
Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore) 2006; 85: 37.
Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987; 13: 531.
Wilson, L.D., F.C. Detterbeck, and J. Yahalom. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med, 2007; 356: 1862-9.
Dombernowsky P, Hansen HH. Combination chemotherapy in the management of superior vena caval obstruction in small-cell anaplastic carcinoma of the lung. Acta Med Scand 1978; 204: 513.
Kvale PA, Selecky PA, Prakash UB. American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 368.
Dondelinger RF, Goffette P, Kurdziel JC, Roche A. Expandable metal stents for stenoses of the ve- nae cavae and large veins. Semin Intervent Radiol 1991; 8: 252–63.
Wurschmidt F, Bunemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys 1995; 33: 77–82.
Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small cell lung cancer. Arch Intern Med 1993; 153: 384–7
Charnsangavej C, Carrasco CH, Wallace S, et al. Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents. Radiology, 1986; 161: 295-8.
Gauden SJ. Superior vena cava syndrome induced by bronchogenic carcinoma: is this an oncological emergency? Australas Radiol 1993; 37: 363-6.
Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction. Is it a medical emergency? Am J Med, 1981; 70: 1169-74.
Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Intervent Radiol 2006; 29: 319.
Oudkerk M, Kuijpers TJ, Schmitz PI, et al. Self-expanding metal stents for palliative treatment of superior vena caval syndrome. Cardiovasc Intervent Radiol 1996; 19: 146.
Nagata T, Makutani S, Uchida H, et al. Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Intervent Radiol 2007; 30: 959.
Lanciego C, Chacón JL, Julián A, et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. AJR Am J Roentgenol 2001; 177: 585.
Martins SJ, Pereira JR. Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol 1999; 22: 453.

Citation

Besen AA. Efficiency of endovascular stenting in the treatment of malignancy related vena cava superior syndrome: single center experience. Ortadogu Tıp Derg. 2018;10(4):449-53. https://doi.org/10.21601/ortadogutipdergisi.457666

Besen, A. A. (2018). Efficiency of endovascular stenting in the treatment of malignancy related vena cava superior syndrome: single center experience. Ortadoğu Tıp Dergisi, 10(4), 449-453. https://doi.org/10.21601/ortadogutipdergisi.457666

Besen, A. A. (2018). Efficiency of endovascular stenting in the treatment of malignancy related vena cava superior syndrome: single center experience. Ortadoğu Tıp Dergisi, 10(4), pp. 449-453. https://doi.org/10.21601/ortadogutipdergisi.457666

Besen AA. Efficiency of endovascular stenting in the treatment of malignancy related vena cava superior syndrome: single center experience. Ortadogu Tıp Derg. 2018;10(4), 449-453. https://doi.org/10.21601/ortadogutipdergisi.457666

Besen, Ali Ayberk. "Efficiency of endovascular stenting in the treatment of malignancy related vena cava superior syndrome: single center experience". Ortadoğu Tıp Dergisi 2018 10 no. 4 (2018): 449-453. https://doi.org/10.21601/ortadogutipdergisi.457666

Besen, Ali Ayberk "Efficiency of endovascular stenting in the treatment of malignancy related vena cava superior syndrome: single center experience". Ortadoğu Tıp Dergisi, vol. 10, no. 4, 2018, pp. 449-453. https://doi.org/10.21601/ortadogutipdergisi.457666